Conall T. Morgan, MD, MRCPCH, Cedric Manlhiot, BSc, Brian W. McCrindle, MD, MPH, and Anne I. Dipchand, MD, FRCPC

Size: px
Start display at page:

Download "Conall T. Morgan, MD, MRCPCH, Cedric Manlhiot, BSc, Brian W. McCrindle, MD, MPH, and Anne I. Dipchand, MD, FRCPC"

Transcription

1 Outcome, incidence and risk factors for stroke after pediatric heart ation: An analysis of the International Society for Heart and Lung Transplantation Registry Conall T. Morgan, MD, MRCPCH, Cedric Manlhiot, BSc, Brian W. McCrindle, MD, MPH, and Anne I. Dipchand, MD, FRCPC From the Labatt Family Heart Centre, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. KEYWORDS: heart ation; mortality; pediatric; stroke; congenital heart disease; outcome; mechanical support BACKGROUND: In the registry of the International Society for Heart and Lung Transplantation (ISHLT), cerebrovascular accidents are the fifth most common cause for mortality after pediatric heart ation (PHTx), but details are lacking in the literature. The purpose of this analysis of the ISHLT registry was to determine the prevalence, risk factors and outcomes of stroke after PHTx. METHODS: Data from the ISHLT registry (1998 to 2010) were used to identify all patients whose primary ation was performed at o18 years of age. Of the 10,441 s reviewed, 9,837 primary s and 604 res were analyzed. RESULTS: Three hundred thirty-three (3%) patients had a stroke after PHTx; 54% were male, median age at PHTx was 6 years (0 to 17 years), and 44% had a diagnosis of congenital heart disease (CHD). Freedom from stroke was 99% at 1 month, 97% at 5 years, 95% at 10 years and 91% at 20 years post- PHTx. After a stroke, survival at 1 month, 1 year and 5 years was 83%, 69% and 55%, respectively. Multivariable independent risk factors for stroke included a primary diagnosis of congenital heart disease [hazard ratio (HR) 1.4 (1.1 to 1.7), p ¼ 0.01], previous stroke [HR 4.5 (3.2 to 6.2), p o 0.001], history of aborted sudden death [HR 1.5 (1.1 to 2), p ¼ 0.01], ventricular assist device [HR 1.5 (1.1 to 2.2), p ¼ 0.03] or extracorporeal membrane oxygenation [HR 1.7 (1.2 to 2.2), p ¼ 0.01], post-operative dialysis [HR 3.3 (2.3 to 4.7), p o 0.001], infection requiring antibiotics before discharge [HR 1.9 (1.4 to 2.5), p o 0.001], pacemaker implantation [HR 1.6 (1 to 2.5), p ¼ 0.04] or drug-treated hypertension [HR 1.4 (1.1 to 1.8), p ¼ 0.003] during follow-up. CONCLUSIONS: Stroke after pediatric heart ation is associated with increased mortality. Congenital heart disease and mechanical support both portend greater risk, in addition to markers of increased pre- and post- medical acuity. J Heart Lung Transplant 2016;35: r 2016 International Society for Heart and Lung Transplantation. All rights reserved. Reprint requests: Anne I. Dipchand, MD, FRCPC, Labatt Family Heart Centre, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada. Telephone: þ Fax: address: anne.dipchand@sickkids.ca /$ - see front matter r 2016 International Society for Heart and Lung Transplantation. All rights reserved. Pediatric heart ation continues to grow worldwide since the first ation in Congenital heart disease (CHD) represents the most common indication for ation, followed closely by cardiomyopathy. 1 The first year after ation has the highest risk of mortality, with graft failure and technical issues being the

2 598 The Journal of Heart and Lung Transplantation, Vol 35, No 5, May 2016 most common cause of death (30%), followed by multiorgan failure (16%), infection (14%) and rejection (12%). 1 Importantly, cerebrovascular events represent the fifth most common cause of mortality in the early post-operative period (10%). 1 The incidence of stroke in children is estimated at 2.6 per 100,000 per year. 2 Patients with CHD are at higher risk for acute ischemic stroke. 3 Almost one third of pediatric patients with acute ischemic stroke have CHD. 4 Risk factors for stroke in this group include a prothrombotic condition, a mechanical valve and an acute illness at the time of the stroke. 5 The risk of peri-operative stroke increases in those patients with CHD who are older at the time of surgery and in those who undergo reoperation or have a longer duration of cardiopulmonary bypass. 4 Overall, the frequency of stroke after surgery for CHD is low, occurring in just over 0.5% of cases, 4 but has been reported to be as high as 3%. 6 In those patients who have had a stroke, 25% occur after a surgical or catheter-based procedure. 7 Recurrence of acute ischemic stroke in patients with CHD occurs in up to 30%. 5,8,9 Although approximately one third of pediatric patients after stroke remain asymptomatic, it is a major source of morbidity and mortality, with just over a third having a seizure disorder or a persistent neurologic deficit and 20% dying after acute ischemic stroke. 9 The burden of stroke in the pediatric heart population is not well known. According to the registry of the International Society for Heart and Lung Transplantation (ISHLT), cerebrovascular accidents represent the fifth most common cause of death after pediatric heart ation (PHTx). The purpose of this analysis of the ISHLT registry was to determine the prevalence, risk factors and outcomes of stroke after PHTx. Methods Study design This study was a retrospective cohort analysis of ISHLT registry s performed from 1988 to The ISHLT registry is an international longitudinal voluntary database that collects data from the time of and throughout follow-up. Study population Heart recipients whose primary was performed at o18 years of age were included in our study data. Those patients who had any stroke, irrespective of etiology, were the focus of our analysis. The comparison group included all ations, both primary and reations, within the registry over the same time period. Patients who underwent multiorgan ation were excluded from the analysis. Data collection Risk factors for stroke were divided into patients characteristics, pre- characteristics, characteristics, post complications and complications during follow-up. Outcomes were evaluated at the time of yearly follow-up. Statistical analysis Data are described as mean with standard deviation or as median with the 5th and 95th percentiles and frequencies. Variables were excluded when there were no events in the patient population, when there was a high level of missing data (470%), and wherever rates were o1% or variables were considered not relevant to the analysis. Time-related events (morbid events and survival) were modeled in multiphase parametric hazard models that decompose risk over time in up to 3 additive, overlapping phases of risk (descriptively labeled as early, constant and late, but actually representing different mathematical functions to model specific patterns of event distribution over time). The analysis was performed using the HAZARD procedure for SAS available from A complete mathematical description and validation of the procedure has been published. 10 Associations between patients characteristics and hazard of stroke were first tested at the univariable level. Associations with p o 0.10 were then included in a multivariable regression model with backward selection of variables to obtain a final model. Bootstrap bagging resampling (500 random samples) was used to determine the internal validity of the multivariable risk models using a reliability threshold of 50% (i.e., variable selected in at least 50% of the random samples). Mean imputation was used to account for missing variables. All statistical analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC). Results Patients characteristics Patients characteristics are summarized in Table 1. Univariable risk factors for stroke are summarized in Table 2 and multivariable risk factors are summarized in Table 3. Patients with stroke were more likely to have had: CHD [hazard ratio (HR) 1.31 (1.05 to 1.62), p ¼ 0.02], although the proportion with cardiomyopathy vs CHD was similar in the stroke cohort (46% vs 44%); a pre- history of aborted sudden death [HR 1.63 (1.25 to 2.13), p o 0.001]; previous stroke [HR 6.12 (4.13 to 9.06), p o 0.001]; hospitalization before ation [HR 1.52 (1.17 to 1.97), p ¼ 0.002]; been hospitalized for 431 days (38% vs 29%, p ¼ 0.04); an infection requiring antibiotics before ation [HR 2.08 (1.57 to 2.74), p o 0.001]; a need for dialysis before ation [HR 2.46 (1.15 to 5.24), p ¼ 0.02]; and received a blood transfusion before ation [HR 2.88 (1.06 to 1.46), p ¼ 0.007]. At the time of ation, patients with stroke were more likely to require inotropes [HR 1.26 (1.00 to 1.59), p ¼ 0.05], mechanical ventilation [HR 2.00 (1.56 to 2.56), p o 0.001] or mechanical circulatory support in the form of a ventricular assist device (VAD) [HR 2.17 (1.55 to 3.04), p o 0.001] or extracorporeal membrane oxygenation (ECMO) [HR 2.84 (1.96 to 4.11), p o 0.001]. Reation [HR 1.76 (1.17 to 2.66), p ¼ 0.007] and later year of ation was also associated with stroke [HR 1.11 (1.08 to 1.13)]. Risk factors that remained significant for stroke on multivariable analyses included CHD [HR 1.35 (1.08 to 1.69), p ¼ 0.009], a history of aborted sudden death [HR 1.48 (1.11 to 1.97), p ¼ 0.007], later year

3 Morgan et al. Stroke After PHTx 599 Table 1 Patients Demographics and Pre-ation Characteristics N Value (%) Recipient age (years) 10,441 o1 year 2,499 (24%) 1 10 years 3,608 (35%) years 4,176 (40%) 418 years 159 (2%) Male gender 5,963 (57%) Primary diagnosis 10,441 Cardiomyopathy 5,508 (53%) Dilated cardiomyopathy 4,162 Hypertrophic cardiomyopathy 234 Myocarditis 442 Restrictive cardiomyopathy 481 Other cardiomyopathy 189 Congenital heart disease 3,873 (37%) Reation 563 (5%) Other 497 (5%) Admission status immediately 3,336 before ation Admitted day of 1,314 (39%) or before Admitted o31 days 1,040 (31%) Admitted 431 days 982 (29%) Medical condition at time of 7,096 Not hospitalized 2,358 (33%) Inpatient but not in ICU 900 (13%) In ICU 3,838 (54%) History of anti-arrhythmics or 5,490 1,104 (20%) amiodarone use History of symptomatic 5, (2%) cerebrovascular disease Cerebrovascular event before 5, (4%) History of dialysis before 5, (2%) History of drug-treated systemic 5, (14%) hypertension Infection requiring IV therapy 5, (17%) 2 weeks before Aborted sudden death before 5,190 1,187 (23%) Patient on life support at time of 6,819 ECMO 407 (6%) Inotropes 3,153 (46%) PGE 381 (6%) Ventilator 1,503 (22%) VAD 636 (9%) ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; PGE, prostaglandin estradiol; VAD, ventricular assist device. [HR 1.09 (1.07 to 1.12), p o 0.001], previous stroke [HR 4.47 (3.22 to 6.19), p o 0.001] and need for either VAD [HR 1.51 (1.05 to 2.19), p ¼ 0.03] or ECMO [HR 1.70 (1.15 to 2.19), p ¼ 0.007]. Peri- and post-operative characteristics There were no relevant donor factors that impacted the risk of stroke in this large cohort of PHTx recipients. Patients with stroke had a longer ischemic time per 60 minutes [HR 1.13 (1.04 to 1.22), p ¼ 0.004] and an overall longer postation length of stay per 10 days [HR 1.08 (1.06 to 1.10), p o 0.001]. After ation, they were more likely to have required dialysis before discharge [HR 5.2 (3.77 to 7.19), p o 0.001], cardiac reoperation before discharge [HR 3.12 (2.22 to 4.38), p o 0.001], or infection requiring antibiotics before discharge [HR 2.68 (2.09 to 3.44), p o 0.001]. During follow-up, patients with stroke Table 2 Univariable Risk Factors Associated With Any Stroke Univariable risk factors HR (95% CI) p-value Patient factors Year of ation 1.11 ( ) o0.001 (per year) Diagnosis of congenital heart 1.31 ( ) 0.02 disease Reation 1.76 ( ) History of stroke before 6.12 ( ) o0.001 Drug-treated infection before 2.08 ( ) o0.001 Aborted sudden death before 1.63 ( ) o0.001 Dialysis before 2.46 ( ) 0.02 Blood transfusion before 2.88 ( ) 0.04 Hospitalization before 1.52 ( ) Lower cardiac output before 1.25 ( ) (liters/min) Support at the time of : inotropic support 1.26 ( ) 0.05 Support at the time of 2.00 ( ) o0.001 : ventilation Support at the time of 2.17 ( ) o0.001 : VAD Support at the time of 2.84 ( ) o0.001 : ECMO Operative factors Duration of hospital stay 1.08 ( ) o0.001 (per 10 days) Duration of ischemic time 1.13 ( ) (per 60 minutes) Post- factors Post- cardiac 3.12 ( ) o0.001 reoperation before hospital discharge Post- dialysis before 5.20 ( ) o0.001 hospital discharge Post- drug-treated 2.68 ( ) o0.001 infection before hospital discharge Pacemaker implantation during follow-up 1.55 ( ) 0.06 Any drug-treated hypertension 1.64 ( ) o0.001 during follow-up Any hospitalization for infection during follow-up 1.53 ( ) ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; VAD, ventricular assist device.

4 600 Table 3 Multivariable Model of Risk Factors Associated With Any Stroke The Journal of Heart and Lung Transplantation, Vol 35, No 5, May 2016 Multivariable risk factors Rel (%) HR (95% CI) p-value Patient factors Year of ation (per year) 100% 1.09 ( ) o0.001 Diagnosis of congenital heart disease 81% 1.35 ( ) History of stroke before 100% 4.47 ( ) o0.001 Aborted sudden death before 88% 1.48 ( ) Lower cardiac output before (liters/min) 84% 1.23 ( ) Support at the time of : VAD 68% 1.51 ( ) 0.03 Support at the time of : ECMO 74% 1.70 ( ) Post- factors Post- cardiac reoperation before hospital discharge 96% 2.02 ( ) o0.001 Post- dialysis before hospital discharge 100% 3.29 ( ) o0.001 Post- drug-treated infection before hospital discharge 100% 1.91 ( ) o0.001 Pacemaker implantation during follow-up 61% 1.58 ( ) 0.04 Any drug-treated hypertension during follow-up 92% 1.41 ( ) ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; Rel, reliability in bootstrap samples; VAD, ventricular assist device. were more likely to have needed a pacemaker [HR 1.55 (0.98 to 2.44), p ¼ 0.06], re-hospitalization for infection after discharge [HR 1.53 (1.20 to 1.94), p ¼ 0.001] and treatment for drug-related hypertension [HR 1.64 (1.28 to 2.10), p o 0.001]. At multivariable analyses, post- need for dialysis before discharge remained the strongest independent risk factor for stroke [HR 3.29 (2.30 to 4.72), p o 0.001]; other strong predictors were cardiac reoperation before discharge [HR 2.02 (1.40 to 2.92), p o 0.001] and post-ation infection requiring antibiotics before discharge [HR 1.91 (1.44 to 2.53), p o 0.001]. At followup, the need for a pacemaker [HR 1.58 (1.01 to 2.47), p ¼ 0.04] and drug-treated hypertension [HR 1.41 (1.12 to 1.78), p ¼ 0.003] remained as independent risk factors for stroke. Overall outcomes Freedom from stroke in PHTx recipients was 99% at 1 month, 97% at 5 years, 95% at 10 years and 91% at 20 years. Figure 1 depicts survival after a stroke post; survival at 1 month, 1 year and 5 years was 83%, 69% and 55%, respectively, which compared unfavorably to patients without stroke. disease are known to be at greater risk for stroke than the general population. Hoffman et al 11 reported an overall incidence of 132 of 100,000 per year, 16-fold higher than the reported incidence in the general pediatric population of between 2 and 8 of 100,000 per year. 12,13 In our population, not surprisingly, a diagnosis of congenital heart disease was a strong independent risk factor for stroke. Previous stroke was the greatest independent risk factor for an additional stroke in our population. Stroke recurrence risk in the CHD population is reported to be as high as 27%, but lower (around 20%) if the primary stroke was not procedurally related. 5 Recurrence of stroke in the non-chd pediatric population is rare, 14 so CHD and the need for repeated surgery or catheter-based interventions may confer an ongoing risk for stroke in this population. Patients with single-ventricle circulations or mechanical circulatory support, such as VAD or ECMO, are at even greater risk of stroke. Reported rates of stroke while on a VAD range between 28% and 34%. Almond et al 15 undertook a large multicenter study of 204 children supported by a Berlin Heart EXCOR device. Stroke was found in 33% of patients and was the leading cause of death. Thromboembolic strokes outnumbered hemorrhagic stroke by more than double. In 2012, Fraser et al 16 prospectively compared a cohort of 24 patients with a VAD with a Discussion This analysis from the ISHLT registry has included the largest cohort of pediatric patients with cerebrovascular events/stroke after heart ation. Stroke after ation is associated with decreased short- and long-term survival with risk factors for stroke that reflect sicker patients both pre- and during the acute post admission. Post- morbidities related with stroke included renal dysfunction, arrhythmia, hypertension and infection. There is a paucity of data in the literature regarding the outcomes and risk factors for stroke in the PHTx population; thus, our study has provided valuable insight into this rare phenomenon. Children with congenital and acquired heart Figure 1 Survival post- after a stroke.

5 Morgan et al. Stroke After PHTx 601 historical control group undergoing ECMO. Stroke occurred in 29% in both groups of patients. In our population, patients on ECMO and patients requiring a VAD at the time of were more likely to have a stroke. The need for pre- and post-operative dialysis is an interesting predictor for stroke after ation. Both dialysis after ation and pre-existing renal dysfunction have been well described as predictors for increased short- and long-term mortality in the heart population, 1,17 and the phenomenon of decreased renal function over time after heart ation was not unexpected. 18 In this study, we did not find pre-existing renal dysfunction (abnormal pre creatinine) to be a predictor for stroke. The need for pre- and post-operative dialysis may be a surrogate marker for a cohort of patients who are sicker after and therefore at greater risk of either ischemic or hemorrhagic stroke. There have been no published studies or case reports of the association with dialysis and stroke in the pediatric population. Therefore, this finding would prompt greater neurologic surveillance of this group of patients. Longer hospital stay, pre- need for inotropes and mechanical ventilation, longer bypass times, mechanical circulatory support such as ECMO or VAD, greater need for reoperation before discharge and longer dependence on inotropy post-ation, like dialysis, are all indicators for prediction of stroke. This likely represents a population of patients who are more complex and more unwell before and certainly after ation. Patients who require antibiotics for infection before discharge are twice as likely to have a stroke. We are not sure why this is so, but systemic inflammation leading to a pro-thrombotic state may be a contributor. 19,20 Similarly to the aforementioned predictors for stroke, infection may represent a sicker group of patients who have spent a longer time in hospital and therefore at greater risk of nosocomial infection. Hypertension after ation and need for pacemaker insertion are not unexpected risk factors for stroke. Hypertension is a common morbidity after heart ation, reported in as many as 25% of recipients at any given time post-, with a cumulative incidence as high as 60%. 21 It is easy to postulate that hypertension that is sub-optimally controlled could predispose to stroke. Similarly, the need for a pacemaker likely implies the presence of arrhythmia, which is a risk factor for thromboembolic events and subsequent stroke. We found that stroke is a relatively uncommon morbidity in the heart population, with 95% of patients free from stroke at 10 years. Although stroke in this population tends to be non-fatal, it does lead to increased short- and long-term mortality. As highlighted earlier, this may represent a cohort of patients with increased medical acuity and complexity before, and a longer, more complicated post- course. Study limitations Our study has all the inherent limitations expected of a retrospective, voluntary, multi-institutional investigation, including incomplete data, variations in reporting of adverse events and different patient data analyzed at different timepoints. The type of stroke, whether embolic or hemorrhagic, was not known and thus makes it harder to identify applicable risk factors. However, this is the largest cohort of pediatric heart patients and its value outweighs its limitations. Pediatric stroke is a rare phenomenon, so further knowledge about this high-risk population would be beneficial. In conclusion, stroke after PHTx is a relatively uncommon yet important finding, because the presence of stroke is associated with worse short- and long-term survival. Patients with congenital heart disease and those with previous stroke are at greater risk for stroke. Disclosure statement The authors have no conflicts of interest to disclose. References 1. Dipchand AI, Kirk R, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official pediatric heart ation report 2013; Focus theme: age. J Heart Lung Transplant 2013;32: Schoenberg BS, Mellinger JF, Schoenberg DG. Cerebrovascular disease in infants and children: a study of incidence, clinical features, and survival. Neurology 1978;28: Gardner TJ, Horneffer PJ, Manolio TA, et al. Stroke following coronary artery bypass grafting: a ten-year study. Ann Thorac Surg 1985;40: Domi T, Edgell DS, McCrindle BW, et al. Frequency, predictors, and neurologic outcomes of vaso-occlusive strokes associated with cardiac surgery in children. Pediatrics 2008;122: Rodan L, McCrindle BW, Manlhiot C, et al. Stroke recurrence in children with congenital heart disease. Ann Neurol 2012;72: Fallon P, Aparicio JM, Elliott MJ, et al. Incidence of neurological complications of surgery for congenital heart disease. Arch Dis Child 1995;72: Mackay MT, Wiznitzer M, Benedict SL, et al. Arterial ischemic stroke risk factors: the International Pediatric Stroke Study. Ann Neurol 2011; 69: Ganesan V, Prengler M, Wade A, et al. Clinical and radiological recurrence after childhood arterial ischemic stroke. Circulation 2006; 114: Lanthier S, Carmant L, David M, et al. Stroke in children: the coexistence of multiple risk factors predicts poor outcome. Neurology 2000;54: Blackstone EH, Naftel DC, Turner ME. The decomposition of timevarying hazard into phases, each incorporating a separate stream of concomitant information. J Am Stat Assoc 1986;81: Hoffman JL, Mack GK, Minich LL, et al. Failure to impact prevalence of arterial ischemic stroke in pediatric cardiac patients over three decades. Congenit Heart Dis 2011;6: Mallick AA, Ganesan V, Kirkham FJ, et al. Childhood arterial ischaemic stroke incidence, presenting features, and risk factors: a prospective population-based study. Lancet Neurol 2014;13: Fullerton HJ, Wu YW, Zhao S, et al. Risk of stroke in children: ethnic and gender disparities. Neurology 2003;61: Fullerton HJ, Wu YW, Sidney S, et al. Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging. Pediatrics 2007;119: Almond CS, Morales DL, Blackstone EH, et al. Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart ation in US children. Circulation 2013;127:

6 602 The Journal of Heart and Lung Transplantation, Vol 35, No 5, May Fraser CD, Jaquiss RDB, Rosenthal DN, et al. Prospective trial of a pediatric ventricular assist device. N Engl J Med 2012;367: Kavarana MN, Savage A, O Connell R, et al. Composite risk factors predict survival after ation for congenital heart disease. J Thorac Cardiovasc Surg 2013;146: Feingold B, Zheng J, Law YM, et al. Risk factors for late renal dysfunction after pediatric heart ation: a multi-institutional study. Pediatr Transplant 2011;15: Lippi G, Favaloro EJ, Montagnana M, et al. C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med 2010;48: Järvisalo MJ, Harmoinen A, Hakanen M, et al. Elevated serum C- reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol 2002;22: Roche SL, O Sullivan JJ, Kantor PF. Hypertension after pediatric cardiac ation: detection, etiology, implications and management. Pediatr Transplant 2010;14:

Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients

Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients

More information

Heart-lung transplantation: adult indications and outcomes

Heart-lung transplantation: adult indications and outcomes Brief Report Heart-lung transplantation: adult indications and outcomes Yoshiya Toyoda, Yasuhiro Toyoda 2 Temple University, USA; 2 University of Pittsburgh, USA Correspondence to: Yoshiya Toyoda, MD,

More information

Transfusion & Mortality. Philippe Van der Linden MD, PhD

Transfusion & Mortality. Philippe Van der Linden MD, PhD Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:

More information

Effect of ABO-Incompatible Listing on Infant Heart Transplant Waitlist Outcomes: Analysis of the United Network for Organ Sharing (UNOS) Database

Effect of ABO-Incompatible Listing on Infant Heart Transplant Waitlist Outcomes: Analysis of the United Network for Organ Sharing (UNOS) Database FEATURED ARTICLES Effect of ABO-Incompatible Listing on Infant Heart Transplant Waitlist Outcomes: Analysis of the United Network for Organ Sharing (UNOS) Database Melanie D. Everitt, MD, a,b,c Amy E.

More information

Pediatric Mechanical Circulatory Support (MCS)

Pediatric Mechanical Circulatory Support (MCS) Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children s Hospital Medical Center The University of Cincinnati

More information

Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis

Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil

More information

Transplant in Pediatric Heart Failure

Transplant in Pediatric Heart Failure Transplant in Pediatric Heart Failure Francis Fynn-Thompson, MD Co-Director, Center for Airway Disorders Surgical Director, Pediatric Mechanical Support Program Surgical Director, Heart and Lung Transplantation

More information

LVAD Complications, Recovery

LVAD Complications, Recovery LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,

More information

A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD

A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist

More information

AllinaHealthSystem 1

AllinaHealthSystem 1 : Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory

More information

Bridge to Heart Transplantation

Bridge to Heart Transplantation Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant

More information

Implantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013

Implantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013 Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective

More information

ECMO CPR. Ravi R. Thiagarajan MBBS, MPH. Cardiac Intensive Care Unit

ECMO CPR. Ravi R. Thiagarajan MBBS, MPH. Cardiac Intensive Care Unit ECMO CPR Ravi R. Thiagarajan MBBS, MPH Staff Intensivist Cardiac Intensive Care Unit Children s Hospital Boston PCICS 2008, Miami, FL No disclosures Disclosures Outline Outcomes for Pediatric in-hospital

More information

The Ross Procedure: Outcomes at 20 Years

The Ross Procedure: Outcomes at 20 Years The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:

More information

Heart Transplant. Policy Number: Last Review: 8/2018 Origination: 8/2001 Next Review: 8/2019

Heart Transplant. Policy Number: Last Review: 8/2018 Origination: 8/2001 Next Review: 8/2019 Heart Transplant Policy Number: 7.03.09 Last Review: 8/2018 Origination: 8/2001 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for a heart transplant

More information

ECMO vs. CPB for Intraoperative Support: How do you Choose?

ECMO vs. CPB for Intraoperative Support: How do you Choose? ECMO vs. CPB for Intraoperative Support: How do you Choose? Shaf Keshavjee MD MSc FRCSC FACS Director, Toronto Lung Transplant Program Surgeon-in-Chief, University Health Network James Wallace McCutcheon

More information

Chairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine

Chairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine Leonard N. Girardi, M.D. Chairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine New York, New York Houston Aortic Symposium Houston, Texas February 23, 2017 weill.cornell.edu

More information

Medical Policy. MP Heart Transplant. BCBSA Ref. Policy: Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery

Medical Policy. MP Heart Transplant. BCBSA Ref. Policy: Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Medical Policy MP 7.03.09 BCBSA Ref. Policy: 7.03.09 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 2.01.68 Laboratory Tests for Rejection 2.04.56 Immune Cell Function

More information

Ischemic Ventricular Septal Rupture

Ischemic Ventricular Septal Rupture Ischemic Ventricular Septal Rupture Optimal Management Strategies Juan P. Umaña, M.D. Chief Medical Officer FCI Institute of Cardiology Disclosures Abbott Mitraclip Royalties Johnson & Johnson Proctor

More information

Policy Specific Section: May 16, 1984 April 9, 2014

Policy Specific Section: May 16, 1984 April 9, 2014 Medical Policy Heart Transplant Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Transplant Original Policy Date: Effective Date: May 16, 1984 April 9, 2014 Definitions

More information

CHANGING THE WAY HEART FAILURE IS TREATED. VAD Therapy

CHANGING THE WAY HEART FAILURE IS TREATED. VAD Therapy CHANGING THE WAY HEART FAILURE IS TREATED VAD Therapy VAD THERAPY IS BECOMING AN ESSENTIAL PART OF HEART FAILURE PROGRAMS AROUND THE WORLD. Patients with advanced heart failure experience an impaired quality

More information

The Gold Standard in Pediatric VAD Therapy A Compilation of Publications Demonstrating the Clinical Excellence of EXCOR Pediatric

The Gold Standard in Pediatric VAD Therapy A Compilation of Publications Demonstrating the Clinical Excellence of EXCOR Pediatric EXCOR Pediatric The Gold Standard in Pediatric VAD Therapy A Compilation of Publications Demonstrating the Clinical Excellence of EXCOR Pediatric EXCOR Pediatric The Gold Standard in Pediatric VAD Therapy

More information

CARDIOVASCULAR SURGERY

CARDIOVASCULAR SURGERY Volume 107, Number 4 April 1994 The Journal of THORACIC AND CARDIOVASCULAR SURGERY Cardiac and Pulmonary Transplantation Risk factors for graft failure associated with pulmonary hypertension after pediatric

More information

Should infants with perinatal thrombosis be screened for thrombophilia and treated by anticoagulants?

Should infants with perinatal thrombosis be screened for thrombophilia and treated by anticoagulants? Should infants with perinatal thrombosis be screened for thrombophilia and treated by anticoagulants? Shoshana Revel-Vilk, MD MSc Pediatric Hematology Center, Pediatric Hematology/Oncology Department,

More information

Ten yr of pediatric heart transplantation: A report from the Pediatric Heart Transplant Study

Ten yr of pediatric heart transplantation: A report from the Pediatric Heart Transplant Study Pediatr Transplantation 213: 17: 99 111 213 John Wiley & Sons A/S. Pediatric Transplantation DOI: 1.1111/petr.1238 Ten yr of pediatric heart transplantation: A report from the Pediatric Heart Transplant

More information

IMPORTANT REMINDER DESCRIPTION

IMPORTANT REMINDER DESCRIPTION Medical Policy Manual Transplant, Policy No. 02 Heart Transplant Next Review: March 2019 Last Review: April 2018 Effective: May 1, 2018 IMPORTANT REMINDER Medical Policies are developed to provide guidance

More information

Should Orthotopic Heart Transplantation Using Marginal Donors Be Limited to Higher Volume Centers?

Should Orthotopic Heart Transplantation Using Marginal Donors Be Limited to Higher Volume Centers? ORIGINAL ARTICLES: ADULT CARDIAC ADULT CARDIAC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,

More information

Current state of pediatric cardiac transplantation

Current state of pediatric cardiac transplantation Keynote Lecture Series Current state of pediatric cardiac transplantation Anne I. Dipchand Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Canada Correspondence

More information

Evidence-based operational and strategic behavior of

Evidence-based operational and strategic behavior of Closing the Loop: Optimizing Physicians Operational and Strategic Behavior Paul T. Sergeant, MD, PhD, and Eugene H. Blackstone, MD Katholieke Universiteit Leuven, Leuven, Belgium, and The Cleveland Clinic

More information

Management of a Patient after the Bidirectional Glenn

Management of a Patient after the Bidirectional Glenn Management of a Patient after the Bidirectional Glenn Melissa B. Jones MSN, APRN, CPNP-AC CICU Nurse Practitioner Children s National Health System Washington, DC No Disclosures Objectives qbriefly describe

More information

ECMO Primer A View to the Future

ECMO Primer A View to the Future ECMO Primer A View to the Future Todd J. Kilbaugh Assistant Professor of Anesthesiology, Critical Care Medicine, and Pediatrics Director of The ECMO Center at the Children s Hospital of Philadelphia Disclosures

More information

Extracorporeal life support in preoperative and postoperative heart transplant management

Extracorporeal life support in preoperative and postoperative heart transplant management Review Article Page 1 of 6 Extracorporeal life support in preoperative and postoperative heart transplant management Christian A. Bermudez 1, D. Michael McMullan 2 1 Division of Cardiovascular Surgery,

More information

EACTS Adult Cardiac Database

EACTS Adult Cardiac Database EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list

More information

Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD

Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD Disclosures Consultant/Speaker AtriCure Medtronic CryoLife Edwards Abbott Research Funding Abbott Equity Interest Clear Catheter Cleveland Clinic

More information

Heart/Lung Transplant

Heart/Lung Transplant Medical Policy Manual Transplant, Policy No. 03 Heart/Lung Transplant Next Review: March 2019 Last Review: April 2018 Effective: June 1, 2018 IMPORTANT REMINDER Medical Policies are developed to provide

More information

Quality Outcomes Mitral Valve Repair

Quality Outcomes Mitral Valve Repair Quality Outcomes Mitral Valve Repair Moving Beyond Reoperation Rakesh M. Suri, D.Phil. Professor of Surgery 2015 MFMER 3431548-1 Disclosure Mayo Clinic Division of Cardiovascular Surgery Research funding

More information

H. Sonali Magdo 1 Kurt R. Schumacher 2 Sunkyung Yu 2 Robert J. Gajarski 3 Joshua M. Friedland-Little 4. Abstract 1 INTRODUCTION ORIGINAL ARTICLE

H. Sonali Magdo 1 Kurt R. Schumacher 2 Sunkyung Yu 2 Robert J. Gajarski 3 Joshua M. Friedland-Little 4. Abstract 1 INTRODUCTION ORIGINAL ARTICLE Accepted: March 17 DOI:.1111/petr.12938 ORIGINAL ARTICLE Clinical significance of anti- HLA antibodies associated with ventricular assist device use in pediatric patients: A United Network for Organ Sharing

More information

A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery

A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery Arman Kilic, MD 1, Rika Ohkuma, MD 1, J. Trent Magruder, MD 1, Joshua C. Grimm, MD 1, Marc Sussman, MD 1, Eric B. Schneider, PhD 1,

More information

Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease

Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease Kristen Nelson, MD Johns Hopkins University Director, Pediatric Cardiac Critical Care Why Does it Matter? Pediatric

More information

CLINICAL COMMUNIQUE 16 YEAR RESULTS

CLINICAL COMMUNIQUE 16 YEAR RESULTS CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced

More information

Minimally Invasive Stand Alone Cox-Maze Procedure For Patients With Non-Paroxysmal Atrial Fibrillation

Minimally Invasive Stand Alone Cox-Maze Procedure For Patients With Non-Paroxysmal Atrial Fibrillation Minimally Invasive Stand Alone Cox-Maze Procedure For Patients With Non-Paroxysmal Atrial Fibrillation Niv Ad, MD Chief, Cardiac Surgery Inova Heart and Vascular Institute Disclosures Niv Ad: Medtronic

More information

Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes

Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph

More information

Repair or Replacement

Repair or Replacement Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division

More information

Management of Heart Failure in Adult with Congenital Heart Disease

Management of Heart Failure in Adult with Congenital Heart Disease Management of Heart Failure in Adult with Congenital Heart Disease Ahmed Krimly Interventional and ACHD consultant King Faisal Cardiac Center National Guard Jeddah Background 0.4% of adults have some form

More information

Ted Feldman, M.D., MSCAI FACC FESC

Ted Feldman, M.D., MSCAI FACC FESC Support Technologies and High Risk Intervention Patient Selection: When Not to Use Them Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas December 7-10 th, 2014 Ted

More information

Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support

Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support Utpal S Bhalala, MD, FAAP Assistant Professor and Director of Research Pediatric Critical Care

More information

Catheter-based mitral valve repair MitraClip System

Catheter-based mitral valve repair MitraClip System Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular

More information

On-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery

On-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery On-Pump vs. Off-Pump CABG: The Controversy Continues Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery On-pump vs. Off-Pump CABG: The Controversy Continues Conflict

More information

ECMO and VAD implantation

ECMO and VAD implantation 1 Udine ECMO Workshop ECMO and VAD implantation Prof. Tomaso Bottio Division of Cardiac Surgery (Director Prof. Gino gerosa) ECMO Extracorporeal membrane oxygena1on (ECMO) is a rescue therapy to support

More information

OHTAC Recommendation: Internet- Based Device-Assisted Remote Monitoring of Cardiovascular Implantable Electronic Devices

OHTAC Recommendation: Internet- Based Device-Assisted Remote Monitoring of Cardiovascular Implantable Electronic Devices OHTAC Recommendation: Internet- Based Device-Assisted Remote Monitoring of Cardiovascular Implantable Electronic Devices Ontario Health Technology Advisory Committee January 2012 Issue Background The Ontario

More information

ECMO as a Bridge to Heart Transplant in the Era of LVAD s.

ECMO as a Bridge to Heart Transplant in the Era of LVAD s. Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of

More information

Small UIAs, <7 mm in diameter, uncommonly cause aneurysmal symptoms and are the most frequently detected incidentally.

Small UIAs, <7 mm in diameter, uncommonly cause aneurysmal symptoms and are the most frequently detected incidentally. Research grant from Stryker Neurovascular Research grant from Covidien/ Medtronic Consultant and proctor for Stryker Neurovascular Consultant and proctor for Covidien/ Medtronic Consultant for Codman Neurovascular

More information

Changing Demographics in Death After Devastating Brain Injury

Changing Demographics in Death After Devastating Brain Injury Changing Demographics in Death After Devastating Brain Injury Andreas H. Kramer MD MSc FRCPC Departments of Critical Care Medicine & Clinical Neurosciences Foothills Medical Center, University of Calgary

More information

Ischemic Stroke in Critically Ill Patients with Malignancy

Ischemic Stroke in Critically Ill Patients with Malignancy Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min

More information

Outcomes of adults with restrictive cardiomyopathy after heart transplantation

Outcomes of adults with restrictive cardiomyopathy after heart transplantation http://www.jhltonline.org Outcomes of adults with restrictive cardiomyopathy after heart transplantation Eugene C. DePasquale, MD, a Khurram Nasir, MD, MPH, b and Daniel L. Jacoby, MD b From the a Division

More information

Should We Reconsider using Anticoagulation for Biological Tissue Valves

Should We Reconsider using Anticoagulation for Biological Tissue Valves Should We Reconsider using Anticoagulation for Biological Tissue Valves No Disclosures Disclosures Watching grass grow Complete with audio 1 hour 8 minutes 9884 views Subclinical Leaflet Thrombosis in

More information

OPCAB IS NOT BETTER THAN CONVENTIONAL CABG

OPCAB IS NOT BETTER THAN CONVENTIONAL CABG OPCAB IS NOT BETTER THAN CONVENTIONAL CABG Harold L. Lazar, M.D. Harold L. Lazar, M.D. Professor of Cardiothoracic Surgery Boston Medical Center and the Boston University School of Medicine Boston, MA

More information

Long-term results of a strategy of aortic valve repair in the paediatric population: Should we avoid cusp extension?

Long-term results of a strategy of aortic valve repair in the paediatric population: Should we avoid cusp extension? Long-term results of a strategy of aortic valve repair in the paediatric population: Should we avoid cusp extension? Y d Udekem, J Siddiqui, C Seaman, I Konstantinov, J Galati, M Cheung, C Brizard Royal

More information

Is Bigger Better? Does PICU Volume Impact Volume

Is Bigger Better? Does PICU Volume Impact Volume Is Bigger Better? Does PICU Volume Impact Volume Brad Poss, MD, MMM Professor of Pediatrics Associate Dean for Graduate Medical Education University of Utah School of Medicine PICU Attending Physician

More information

A Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial

A Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal

More information

2012 Year In Review In Review. Number of Patients on WaitList as of Number Of Transplants Year. Number Of Patients

2012 Year In Review In Review. Number of Patients on WaitList as of Number Of Transplants Year. Number Of Patients Number Of Patients Number Of Transplants In Review In Review Kidney Kidney Pancreas Pancreas Liver Heart Number of Patients on WaitList as of.. Kidney Kidney Pancreas Liver Heart Number of Donors Number

More information

16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900

16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical

More information

Clinical Policy: Pediatric Heart Transplant

Clinical Policy: Pediatric Heart Transplant Clinical Policy: Reference Number: CP.MP.138 Review Date: 01/19 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description

More information

2014 Year End Review

2014 Year End Review End Review Transplants Kidney Kidney Pancreas Pancreas Liver Heart Number of Patients on WaitList as of.. 99 Number Of Patients 9 Kidney Kidney Pancreas Liver Heart Organ Donor Statistics Atlantic Canada

More information

CORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW

CORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW 2015 PQRS OPTIONS F MEASURES GROUPS: 2015 PQRS MEASURES IN CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP: #43 Coronary Artery Bypass Graft (CABG):

More information

Who does not need a primary preventive ICD?

Who does not need a primary preventive ICD? Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense

More information

Heart Failure Medical and Surgical Treatment

Heart Failure Medical and Surgical Treatment Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February

More information

Thoracic Simulation Allocation Modeling (TSAM) of a 6-Tier Allocation Strategy for Heart Transplant

Thoracic Simulation Allocation Modeling (TSAM) of a 6-Tier Allocation Strategy for Heart Transplant Thoracic Simulation Allocation Modeling (TSAM) of a 6-Tier Allocation Strategy for Heart Transplant Monica Colvin, Melissa Skeans, Liz Robbins, Leah Edwards, Jessica Zeglin, Scott Silvestry, Ryan Davies,

More information

Right Ventricular Failure: Prediction, Prevention and Treatment

Right Ventricular Failure: Prediction, Prevention and Treatment Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:

More information

PREDICTORS OF PROLONGED HOSPITAL STAY

PREDICTORS OF PROLONGED HOSPITAL STAY PREDICTORS OF PROLONGED HOSPITAL STAY IN CARDIAC SURGERY Zuraida Khairudin Faculty of Science Computer and Mathematics, Universiti Teknologi MARA, Malaysia zurai405@salam.uitm.edu.my ABSTRACT quality of

More information

DEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University

DEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University DEMYSTIFYING VADs Nicolle Choquette RN MN Athabasca University Objectives odefine o Heart Failure o VAD o o o o Post Operative Complications Acute Long Term Nursing Interventions What is Heart Failure?

More information

Atrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology

Atrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance

More information

Clinical Investigations

Clinical Investigations Clinical Investigations Outcomes Associated With Preoperative Use of Extracorporeal Membrane Oxygenation in Children Undergoing Heart Operation for Congenital Heart Disease: A Multi-institutional Analysis

More information

Pediatrics. Arrhythmias in Children: Bradycardia and Tachycardia Diagnosis and Treatment. Overview

Pediatrics. Arrhythmias in Children: Bradycardia and Tachycardia Diagnosis and Treatment. Overview Pediatrics Arrhythmias in Children: Bradycardia and Tachycardia Diagnosis and Treatment See online here The most common form of cardiac arrhythmia in children is sinus tachycardia which can be caused by

More information

2017 Year End Review

2017 Year End Review Number Of Patients End Review Transplants 9 9 Kidney Kidney Pancreas Pancreas Liver Heart Number of Patients on WaitList as of..9 Kidney Kidney Pancreas Pancreas Liver Heart Number of Donors Number of

More information

Left Ventricular Assist Devices (LVADs): Overview and Future Directions

Left Ventricular Assist Devices (LVADs): Overview and Future Directions Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,

More information

Site of Interstage Care, Resource Utilization, and Interstage Mortality: A Report from the NPC-QIC Registry

Site of Interstage Care, Resource Utilization, and Interstage Mortality: A Report from the NPC-QIC Registry Schidlow et al 1 Site of Interstage Care, Resource Utilization, and Interstage Mortality: A Report from the NPC-QIC Registry David Schidlow Kimberlee Gauvreau Mehul Patel Karen Uzark David W. Brown For

More information

MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC

MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal

More information

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner

More information

JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012

JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012 SAMUEL TCHWENKO, MD, MPH Epidemiologist, Heart Disease & Stroke Prevention Branch Chronic Disease & Injury Section; Division of Public Health NC Department of Health & Human Services JUSTUS WARREN TASK

More information

Outline. Congenital Heart Disease. Special Considerations for Special Populations: Congenital Heart Disease

Outline. Congenital Heart Disease. Special Considerations for Special Populations: Congenital Heart Disease Special Considerations for Special Populations: Congenital Heart Disease Valerie Bosco, FNP, EdD Alison Knauth Meadows, MD, PhD University of California San Francisco Adult Congenital Heart Program Outline

More information

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators ACC Late Breaking Clinical Trials March 16,

More information

Patient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.

Patient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D. Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined

More information

The Effect of Statin Therapy on Risk of Intracranial Hemorrhage

The Effect of Statin Therapy on Risk of Intracranial Hemorrhage The Effect of Statin Therapy on Risk of Intracranial Hemorrhage JENNIFER HANIFY, PHARM.D. PGY2 CRITICAL CARE RESIDENT UF HEALTH JACKSONVILLE JANUARY 23 RD 2016 Objectives Review benefits of statin therapy

More information

Statistical analysis plan

Statistical analysis plan Statistical analysis plan Prepared and approved for the BIOMArCS 2 glucose trial by Prof. Dr. Eric Boersma Dr. Victor Umans Dr. Jan Hein Cornel Maarten de Mulder Statistical analysis plan - BIOMArCS 2

More information

Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass?

Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass? Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass? A comparison of 30-day complications using the MBSAQIP data registry Sandhya B. Kumar MD, Barbara C. Hamilton MD, Soren Jonzzon,

More information

Mechanical Support in the Failing Fontan-Kreutzer

Mechanical Support in the Failing Fontan-Kreutzer Mechanical Support in the Failing Fontan-Kreutzer Stephanie Fuller MD, MS Thomas L. Spray Endowed Chair in Congenital Heart Surgery Associate Professor, The Perelman School of Medicine at the University

More information

Heart Transplantation for Patients with a Fontan Procedure

Heart Transplantation for Patients with a Fontan Procedure Heart Transplantation for Patients with a Fontan Procedure Kirk R. Kanter MD Professor of Surgery Pediatric Cardiac Surgery Emory University School of Medicine Children s Healthcare of Atlanta Atlanta,

More information

Ramani GV et al. Mayo Clin Proc 2010;85:180-95

Ramani GV et al. Mayo Clin Proc 2010;85:180-95 THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation

More information

Low Cardiac Output in the Pediatric Patient

Low Cardiac Output in the Pediatric Patient Low Cardiac Output in the Pediatric Patient Jeffrey Burns, M.D., M.P.H. Chief, Division of Critical Care Medicine Children s Hospital Boston Associate Professor of Anesthesia and Pediatrics Harvard Medical

More information

Emergency surgery in acute coronary syndrome

Emergency surgery in acute coronary syndrome Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Ablation, radiofrequency, anesthetic considerations for, 479 489 Acute aortic syndrome, thoracic endovascular repair of, 457 462 aortic

More information

How do we define ethnic healthcare disparities? Ethnic Disparity. Cardiovascular Disease in Asians: Are Asians at Increased Risk?

How do we define ethnic healthcare disparities? Ethnic Disparity. Cardiovascular Disease in Asians: Are Asians at Increased Risk? Cardiovascular Disease in Asians: Are Asians at Increased Risk? November 17, 2007 Gordon L. Fung, MD, MPH, PhD, FACC, FAHA, FACP Director, Asian Heart & Vascular Center Clinical Professor of Medicine UCSF

More information

Remodeling of the Remnant Aorta after Acute Type A Aortic Dissection Surgery

Remodeling of the Remnant Aorta after Acute Type A Aortic Dissection Surgery Remodeling of the Remnant Aorta after Acute Type A Aortic Dissection Surgery Are Young Patients More Likely to Develop Adverse Aortic Remodeling of the Remnant Aorta Over Time? Suk Jung Choo¹, Jihoon Kim¹,

More information

ORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION

ORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner

More information

Stayin Alive: Pediatric Advanced Life Support (PALS) Updated Guidelines

Stayin Alive: Pediatric Advanced Life Support (PALS) Updated Guidelines Stayin Alive: Pediatric Advanced Life Support (PALS) Updated Guidelines Margaret Oates, PharmD, BCPPS Pediatric Critical Care Specialist GSHP Summer Meeting July 16, 2016 Disclosures I have nothing to

More information

Presenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose

Presenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material

More information

Understanding the Pediatric Ventricular Assist Device

Understanding the Pediatric Ventricular Assist Device Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center

More information

Postoperative atrial fibrillation is not an innocuous arrhytmia in LAVD patients

Postoperative atrial fibrillation is not an innocuous arrhytmia in LAVD patients Accepted Manuscript Postoperative atrial fibrillation is not an innocuous arrhytmia in LAVD patients Cipriano Abad, MD, PhD, FEBS(Hon, Gen Surg), EBCTS, Stefano Urso, MD, PhD, Bernardino Clavo, MD, PhD

More information